Market Overview

Vetr Issues Strong Buy As Teva Trends Down

Related TEVA
12 Biggest Mid-Day Losers For Wednesday
Benzinga's Top Upgrades, Downgrades For August 16, 2017
Teva Blood Is in the Streets (GuruFocus)

The Vetr crowd on Thursday upgraded its rating for Teva Pharmaceutical Industries Limited (ADR) (NYSE: TEVA) from 3.5 stars (Buy), issued 15 days ago, to 4.5 stars (Strong Buy). Crowd sentiment at the time of the downgrade was mostly bullish, with 81 0percent of Vetr user ratings bullish.

Share price in the biotech company has been on the downtrend throughout most of 2017, experiencing small price bumps following average earnings reports in February and May, the latter of which revealed the company was $30 million shy of analyst sales estimates, but delivered $0.03 over the quarter's EPS estimate.

However, the stock has resumed its downward path, reaching a new 10-year low of $29.67 by the end of May 18.

Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for Teva is up at 34.25, which is still below the average analyst target price of $45.47. Less than 2 percent of Vetr users are holding TEVA in their watch lists.

Latest Ratings for TEVA

Aug 2017CitigroupDowngradesBuyNeutral
Aug 2017BarclaysMaintainsEqual-Weight
Aug 2017Morgan StanleyDowngradesEqual-WeightUnderweight

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Price Target Crowdsourcing Analyst Ratings General


Related Articles (TEVA)

View Comments and Join the Discussion!